Health-related quality of life of daily-life-affected benign essential blepharospasm: Multi-center observational study

Purpose To compare Thais’ health-related quality of life (HRQOL) and severity grading, efficacy and safety in daily-life-affected benign essential blepharospasm (BEB) patients at baseline and after Botulinum toxin type A (BTX-A) treatment. Design Prospective-observational study. Participants BEB patients with Jankovic rating scale (JRS) at least 3 in both severity and frequency graded from 14 institutes nationwide were included from August 2020 to June 2021. Methods Demographic data, HRQOL evaluated by the Thai version of EQ-5D-5L and NEI-VFQ-25 questionnaires, and severity grading score evaluated by Jankovic rating scale (JRS) at baseline, 1, and 3 months after the treatment were collected. The impact of the BTX-A injections and their complications were recorded. Results 184 daily-life-affected BEB patients were enrolled; 159 patients (86.4%) had complete data with a mean age of 61.40±10.09 years. About 88.05% were female, and 10.1% were newly diagnosed. Most of the patients had bilateral involvement (96.9%) and 12.6% had history of BEB-related accident. After BTX-A treatment, HRQOL improved significantly in 4 dimensions of EQ-5D-5L, except self-care. The EQ_VAS (mean±SD) was 64.54±19.27, 75.13±15.37, 73.8±15.85 (p<0.001) and EQ-5D-5L utility score was 0.748±0.23, 0.824±0.19 and 0.807±0.19 at baseline, 1, 3 months after treatment, respectively. From NEI-VFQ-25, HRQOL also improved in all dimensions, except eye pain. The JRS improved in all patients. Self-reported minor adverse events were 22.6%, which mostly resolved within the first month. Conclusion Daily-life-affected BEB impacted HRQOL in most dimensions from both generic and visual-specific questionnaires. BTX-A treatment not only decreased disease severity, but also improved quality of life.

[1]  A. Berardelli,et al.  Measurement Properties of Clinical Scales Rating the Severity of Blepharospasm: A Multicenter Observational Study , 2022, Movement disorders clinical practice.

[2]  M. Hallett,et al.  Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review , 2022, Dystonia.

[3]  M. Hallett,et al.  Diagnostic criteria for blepharospasm: A multicenter international study. , 2021, Parkinsonism & related disorders.

[4]  Jing Yang,et al.  Sex related differences in nonmotor symptoms of patients with idiopathic blepharospasm , 2021, Scientific Reports.

[5]  Rami Mosleh,et al.  COVID‐19 confinement and related well being measurement using the EQ‐5D questionnaire: A survey among the Palestinian population , 2021, International journal of clinical practice.

[6]  J. Jankovic,et al.  Quality of life in isolated dystonia: non-motor manifestations matter , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[7]  J. Hay,et al.  A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L , 2020, Journal of General Internal Medicine.

[8]  L. G. Vu,et al.  Impact of COVID-19 on Economic Well-Being and Quality of Life of the Vietnamese During the National Social Distancing , 2020, Frontiers in Psychology.

[9]  Jianzhong Zheng,et al.  Evaluation of health-related quality of life using EQ-5D in China during the COVID-19 pandemic , 2020, PloS one.

[10]  M. Vidailhet,et al.  Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  V. Tumas,et al.  The Prevalence and Correlation of Non-motor Symptoms in Adult Patients with Idiopathic Focal or Segmental Dystonia , 2019, Tremor and Other Hyperkinetic Movements.

[12]  V. Tumas,et al.  The Prevalence and Correlation of Non-motor Symptoms in Adult Patients with Idiopathic Focal or Segmental Dystonia , 2019, Tremor and other hyperkinetic movements.

[13]  Youn-Shen Bee,et al.  Epidemiology of benign essential blepharospasm: A nationwide population-based retrospective study in Taiwan , 2018, PloS one.

[14]  S. Paus,et al.  Depression in blepharospasm: a question of facial feedback? , 2017, Neuropsychiatric disease and treatment.

[15]  Jing Yang,et al.  Nonmotor symptoms in primary adult‐onset cervical dystonia and blepharospasm , 2016, Brain and behavior.

[16]  M. Jog,et al.  Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[17]  W. Hwang,et al.  Motor vehicle accidents and injuries in patients with idiopathic blepharospasm , 2014, Journal of the Neurological Sciences.

[18]  M. Hallett,et al.  Phenomenology and classification of dystonia: A consensus update , 2013, Movement disorders : official journal of the Movement Disorder Society.

[19]  S. Couch,et al.  Comparison of Preferences Between OnabotulinumtoxinA (Botox) and IncobotulinumtoxinA (Xeomin) in the Treatment of Benign Essential Blepharospasm , 2013, Ophthalmic plastic and reconstructive surgery.

[20]  A. Berardelli,et al.  Age at onset and symptom spread in primary adult‐onset blepharospasm and cervical dystonia , 2012, Movement disorders : official journal of the Movement Disorder Society.

[21]  Michael S. Lee,et al.  Gender Differences in Benign Essential Blepharospasm , 2012, Ophthalmic Plastic and Reconstructive Surgery.

[22]  P. Sathirapanya,et al.  Factors associated with quality of life in hemifacial spasm and blepharospasm during long-term treatment with botulinum toxin , 2011, Quality of Life Research.

[23]  P. Sathirapanya,et al.  Validation of a Disease-Specific Questionnaire for Health-Related Quality of Life in Thai , 2009 .

[24]  C. Cianchetti,et al.  Prevalence of primary blepharospasm in Sardinia, Italy: A service‐based survey , 2006, Movement disorders : official journal of the Movement Disorder Society.

[25]  W. Poewe,et al.  Social stigmatization in patients with cranial and cervical dystonia , 2006, Movement disorders : official journal of the Movement Disorder Society.

[26]  J. Mink,et al.  Relative risk of spread of symptoms among the focal onset primary dystonias , 2006, Movement disorders : official journal of the Movement Disorder Society.

[27]  L. Kline,et al.  Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. , 2006, Archives of ophthalmology.

[28]  A. Karow,et al.  Health‐related quality of life in blepharospasm or hemifacial spasm , 2005, Acta neurologica Scandinavica.

[29]  R. Goldberg,et al.  Benign Essential Blepharospasm , 2005, International ophthalmology clinics.

[30]  D. Weinberger,et al.  Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. , 2003, American journal of ophthalmology.

[31]  G. Defazio,et al.  Epidemiology of primary blepharospasm , 2002, Movement disorders : official journal of the Movement Disorder Society.

[32]  R. Hilker,et al.  Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia , 2001, Journal of neurology, neurosurgery, and psychiatry.

[33]  R. Hays,et al.  Development of the 25-item National Eye Institute Visual Function Questionnaire. , 2001, Archives of ophthalmology.

[34]  D. Martino,et al.  Prevalence of primary blepharospasm in a community of Puglia region, Southern Italy , 2001, Neurology.

[35]  E. Cassetta,et al.  A prevalence study of primary dystonia in eight European countries , 2000, Journal of Neurology.

[36]  S. Yi,et al.  Botulinum a toxin treatment of hemifacial spasm and blepharospasm. , 1993, Journal of Korean medical science.

[37]  C D Marsden,et al.  Blepharospasm: a review of 264 patients. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[38]  J. Nutt,et al.  Epidemiology of focal and generalized dystonia in Rochester, Minnesota , 1988, Movement disorders : official journal of the Movement Disorder Society.

[39]  J Jankovic,et al.  Botulinum A toxin for cranial‐cervical dystonia , 1987, Neurology.